Kamada Raises an Additional US$ 1.5 Million (Approximately) in a Private Allocation of Common Stock

NESS ZIONA, Israel, May 11, 2009 (BUSINESS WIRE) — KAMAF | Quote | Chart | News | PowerRating — Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics announced today that, pursuant to an agreement dated February 23, 2009, it has completed the private allocation of the company’s common stock to Meitav, a leading institutional investor in Israel. The placement resulted in gross proceeds to Kamada of approximately US$1.5 million via private placement memorandum in Israel.

On May 4, 2009, Kamada closed on the sale of approximately US$7 million of its common stock in a private allocation to a select group of investors, including Mr. Ralf Hahn, Chairman of the Board and one of the controlling shareholders, and UDT Med Holdings LLC, New York.

About Kamada

Kamada is a public biopharmaceutical company (TASE:KMDA) developing, producing and marketing a line of specialty life-saving therapeutics using its proprietary chromatographic purification technologies. Licensed and marketed in more than 15 countries, several of these specialty therapeutics and are currently undergoing advanced clinical trials.

The company has recently completed a Phase III clinical trial in the US with its flagship IV Alpha-1 Antitrypsin (AAT) product indicated for treating AAT deficiency and is currently in advanced stages of development of its next generation, inhaled administration AAT for the treatment of various lung diseases including cystic fibrosis and bronchiectasis.

http://www.tradingmarkets.com/.site/news/Stock%20News/2320492/

About Us

PPM is the leading U.S. entrepreneurial firm that specializes in writing private placement memorandums (PPM) and linking investors with entrepreneurs.

Since 1999, the founders of PPM have provided professional business writing services, such as a PPM or business plan, to more than 2,000 businesses worldwide. Our company is considered to be the most cost effective, efficient consultants for private placement memorandum development in the United States. We are Wall Street’s, and by extension, the New York private placement (PPM) leaders.

PPM.co’s main service is the creation of private placement memorandum regulation d (Reg. d) documents. However, we offer much more. In case the entrepreneur needs additional services, such as a business plan, website, or additional legal work, PPM can create one pricing package for all required documentation or service. Because we simultaneously work with many companies both in and out of the U.S., the ability to adapt to the individual needs – as well as to regional and global demands – helps our clients save needed capital and time.

We are leaders in:

• New York Private Placement
• Real Estate Private Placement
• Technology Private Placement
• Debt Private Placement
• Equity Private Placement
• Technology Private Placement Memorandum Writing
• New York Private Placement Memorandum Writing
• Real estate Private Placement Memorandum Writing
• Debt Private Placement Memorandum Writing
• Equity Private Placement Memorandum Writing